Coronavirus disease has many systemic disease symptoms and has severe consequences for the cardiovascular system.
OBJECTIVE
To assess the role of clinical and laboratory indicators in determining the risk of chronic heart failure (CHF) in COVID-19 survivors.
MATERIAL AND METHODS
In total, 151 patients treated in a monoinfectious hospital from 03.11.20 to 10.02.21 with a confirmed diagnosis of COVID-19 were retrospectively selected. Medical history and laboratory data were collected by reviewing electronic medical records. The data included age, gender, body mass index, smoking status, and comorbidities. The laboratory data included the results of hematology and blood chemistry, coagulation, and the levels of acute-phase proteins. The CHF occurrence was used as the study endpoint.
RESULTS AND DISCUSSION
The study patients were divided into two groups depending on the presence of CHF: group 1 included 46 patients with CHF, and group 2 included 105 patients without CHF. The median age was 66.2 (50—92) years; 91 (60.3%) were females. Laboratory tests, such as levels of the hs-C-reactive protein, lactate dehydrogenase, procalcitonin, creatinine, and bilirubin, were statistically significantly different in patients of the study groups, and the median values were higher in patients with CHF. Neutrophil-lymphocyte ratio (NLR) showed statistically significant differences between groups: in patients with CHF, the median was 4.97% compared to 3.62% (p=0.011) in those without CHF. The most significant predictors of an increased risk of CHF were age ≥66 years (OR=8.038, p<0.001), procalcitonin level ≥0.09 ng/mL (increased the CHF risk by 3.8 times, p<0.001), thrombocytopenia ≤220×109/L (p=0.010), an NLR ratio ≥4.11% (p=0.010), and a history of chronic kidney disease (p=0.018).
CONCLUSION
A model has been developed to determine the factors closely associated with the risk of chronic heart failure in COVID-19 survivors.
